Future Growth Opportunities in Generics

The impact of consolidation on market and competitive dynamics

Publication Date	November 2006
Publisher	Business Insights
Product Type	Report
Pages	136
ISBN Number	not applicable
Product Code	RBI00115

Price

£1,495.00
approximately: $2,220 | €1,759

PDF

PRINT £1,545 ($2,294 | €1,818)

Order above formats by FAX

Summary

The number of commercially lucrative drugs coming off patent has catalyzed the growth of the generics industry, creating significant profit opportunities for generics manufacturers. However, this market faces a considerable number of threats, with bulk manufacturers from developing countries becoming internationally competitive and the aggressive actions of branded pharmaceutical marketers in protecting their patent and market position resulting in ramifications for the sector as a whole.

Future Growth Opportunities in Generics provides an in-depth analysis into the direction of the global generics market, evaluating competitive dynamics through a detailed review of major consolidation activity in the sector. Opportunities for future success are also explored, including the potential offered by biosimilars and the increasing focus by governments on healthcare cost containment, enabling you to determine the factors crucial to your success in the global generics market.

Key findings of the report...

The global unbranded generics market was valued at $38bn in 2005, up 14.3% on 2004 sales of $33bn. The generics market has witnessed strong growth over the previous five years and has more than doubled in size since 2001.
Although, historically the US market has enjoyed a higher rate of popularity for new generic entrants, due to increased competition, companies now tend to look into expanding into markets with developing growth potential, such as the under-penetrated markets of the EU and the emerging markets in Asia.
M&A continues to be a main strategy for growth as generics companies continue to vie to enhance their portfolio status, undertake geographic expansion or to gain monopoly in a particular region or therapeutic area, with price pressures and technology access being the key pressures driving acquisition activity.
The generics market appears poised for future growth, with upcoming expiries of blockbuster products forecast to further fuel growth particularly in hormonal cancers, hypertension, dyslipidemia, bacterial infections, viral infections, schizophrenia and epilepsy indications.

Key questions answered in this report

What key strategies are generic companies utilizing in order to increase their market share and ensure healthy profit margins?
Which country markets will see the highest growth and what are the most attractive therapy areas for generics companies to target?
What are the current generic market trends within the major therapy areas of cardiovascular, cancer, gastrointestinal, anti-infectives and CNS?
What is the extent of the threat on branded products from the growth of the global generics market?
How do branded pharmaceutical companies defend against the threat of generics competition?
Which companies are best positioned to succeed in biosimilars?

Top five reasons to order your copy today

Identify the therapeutic areas with the most potential for generic growth and ensure your portfolio is aligned with future market opportunity.
Understand how geographic expansion is one of the major reasons behind recent consolidation in the industry, and evaluate which national markets are poised for growth over the next 5 years.
Evaluate how the market shares of the leading generics companies, such as Novartis, Teva and Mylan will change over the next 5 years, and assess your competitive position within the market.
Discover what key strategies generics companies are utilizing in order to increase market share and achieve a competitive advantage.
Assess the defensive strategies implemented by branded pharmaceutical marketers to protect their patents and delay generic entry, and understand how this affects the generics market place.

Content

Executive Summary
- Generics growth opportunities and branded defense strategies
- Generics market analysis by country and region
- Generics market analysis by therapeutic area
- Leading generics players
- Consolidation in the generics industry
Chapter 1 Generics growth opportunities and branded defense strategies
- Summary
- Introduction
- Key generics growth opportunities
- Availability of off-patent treatments and paragraph IV challenges
- Healthcare cost containment policies
- The biogenerics/biosimilars opportunity
- Mergers and acquisitions
- Defense strategies from branded companies
- Rx-to-OTC switching
- Defensive pricing
- Patent litigation
- Reformulation
- Authorized generics agreements and settlements
- Launching in-house generics
Chapter 2 Generics market analysis by country and region
- Summary
- Introduction
- Regional generics market analysis
- North American market
- Major markets of Latin America
- Major European markets
- Major markets of Central and Eastern Europe
- Japanese market
- Chinese market
- Selected markets in the Asia-Pacific region
Chapter 3 Generics market analysis by therapeutic area
- Summary
- Introduction
- Market breakdown by therapeutic area
- CNS disorders market analysis
- Cardiovascular diseases market analysis
- Alimentary tract and metabolism market analysis
- Cancer market analysis
- Anti-infectives market analysis
- Therapy area forecasts
Chapter 4 Leading generics players
- Summary
- Introduction
- Key players in the global generics market
- Performance of major generics companies by region
- Company portfolio analysis
- Novartis
- Marketed product portfolio
- Forecast sales
- Teva
- Marketed product portfolio
- Forecast sales
- Mylan
- Marketed product portfolio
- Forecast sales
- Ratiopharm
- Marketed product portfolio
- Forecast sales
- Watson
- Marketed product portfolio
- Forecast sales
- Merck KGaA
- Marketed product portfolio
- Forecast sales
- Ivax
- Marketed product portfolio
- Forecast sales
- Apotex
- Marketed product portfolio
- Forecast sales
- Par
- Marketed product portfolio
- Forecast sales
- Alpharma
- Marketed product portfolio
- Forecast sales
Chapter 5 Consolidation in the generics industry
- Summary
- Introduction
- Factors influencing M&A deals across markets
- Key deals in emerging markets
- Dr. Reddy's
- Betapharm acquisition
- Roche's API facility acquisition
- Trigenesis acquisition
- Ranbaxy
- Mundogen acquisition
- Ethimed acquisition
- Terapia acquisition
- Egis
- Serdix acquisition
- Zentiva
- Sicomed acquisition
- Key deals in Western Europe
- Sandoz/Novartis
- Sabex acquisition
- Hexal/Eon acquisition
- Stada Arzneimittel
- Hemofarm acquisition
- Nizpharm acquisition
- Other acquisitions
- Ratiopharm
- Magnafarma BV acquisition
- vi Pulmotec acquisition
- Ribosepharm acquisition
- Merck KGaA
- Prasfarma acquisition
- NM Pharma acquisition
- Actavis
- Alpharma acquisition
- Amide acquisition
- Sindan acquisition
- Keri Pharma acquisition
- Key deals in the US
- Watson
- Amarin acquisition
- Sekhsaria acquisition
- Andrx acquisition
- Barr
- Pliva acquisition
- Mylan
- Matrix Labs acquisition
- Perrigo
- Agis acquisition
- Other key deals
- Teva
- Ivax acquisition
- Conclusions
Chapter 6 Appendix
- Glossary
- Index
List of Figures
- Figure 1.1: Generics company growth strategies
- Figure 1.2: Number of ANDA and first-to-file approvals, 2001-2006
- Figure 1.3: Average monthly ANDA and first-to-file approvals, 2001-2006
- Figure 1.4: Pharmaceutical cost containment policies in developed and developing markets
- Figure 2.5: Market dynamics in the global unbranded generics market by country, 2004-05
- Figure 3.6: Market breakdown of the major therapy classes in the global unbranded generics market, 2001 & 2005
- Figure 3.7: Market dynamics of the major CNS unbranded generics, 2005
- Figure 3.8: Market dynamics of the major cardiovascular unbranded generics, 2005
- Figure 3.9: Market dynamics of the major alimentary tract and metabolism generics, 2005
- Figure 3.10: Market dynamics of the leading cancer unbranded generics, 2005
- Figure 3.11: Market dynamics of the leading anti-infectives unbranded generics, 2005
- Figure 4.12: Performance of major players in the global generics market, 2001 & 2005
- Figure 5.13: Factors shaping M&A deals across the US, EU and emerging markets
- Figure 5.14: Key generics M&A by region, 2004-06
- Figure 5.15: Competitive pressures influencing generics M&A strategies, 2005-06
List of Tables
- Table 2.1: Sales of unbranded generics by country, 2004-05
- Table 2.2: Sales of unbranded generics in North America, 2004-05
- Table 2.3: Sales of unbranded generics in Latin America, 2004-05
- Table 2.4: Sales of unbranded generics in major Western European markets, 2004-05
- Table 2.5: Sales of unbranded generics in major Central and Eastern European markets, 2004-05
- Table 2.6: Sales of unbranded generics in Japan, 2004-05
- Table 2.7: Sales of unbranded generics in China, 2004-05
- Table 2.8: Sales of unbranded generics in Asia-Pacific, 2001-05
- Table 3.9: Sales by major therapeutic area across the global unbranded generics market, 200405
- Table 3.10: Sales of major molecules in the global CNS unbranded generics market, 200405
- Table 3.11: Sales of major molecules in the global cardiovascular unbranded generics market, 200405
- Table 3.12: Sales of major molecules in the alimentary tract and metabolic disorders global unbranded generics market, 200405
- Table 3.13: Sales of major molecules in the global cancer unbranded generics market, 200405
- Table 3.14: Sales of major molecules in the global anti-infectives unbranded generics market, 200405
- Table 3.15: Forecast global unbranded generics sales by therapy area, 2005-11
- Table 4.16: Leading ten generics companies by global unbranded generics sales, 2004-05
- Table 4.17: Leading generics companies by global generics sales, 2004-05
- Table 4.18: Leading products in Novartis' generics portfolio, 2004-05
- Table 4.19: Forecast sales of Novartis' current generics portfolio, 2005-2011
- Table 4.20: Leading products in Teva's generics portfolio, 2004-05
- Table 4.21: Forecast sales of Teva's current generics portfolio, 2005-2011
- Table 4.22: Leading products in Mylan's generics portfolio, 2004-05
- Table 4.23: Forecast sales of Mylan's current generics portfolio, 2005-2011
- Table 4.24: Leading products in Ratiopharm's generics portfolio, 2004-05
- Table 4.25: Forecast sales of Ratiopharm's current generics portfolio, 2005-2011
- Table 4.26: Leading products in Watson's generics portfolio, 2004-05
- Table 4.27: Forecast sales of Watson's current generics portfolio, 2005-2011
- Table 4.28: Leading products in Merck KGaA's generics portfolio, 2004-05
- Table 4.29: Forecast sales of Merck KGaA's current generics portfolio, 2005-2011
- Table 4.30: Leading products in Ivax's generics portfolio, 2004-05
- Table 4.31: Forecast sales of Ivax's current generics portfolio, 2005-2011
- Table 4.32: Leading products in Apotex's generics portfolio, 2004-05
- Table 4.33: Forecast sales of Apotex's current generics portfolio, 2005-2011
- Table 4.34: Leading products in Par's generics portfolio, 2004-05
- Table 4.35: Forecast sales of Par's current generics portfolio, 2005-2011
- Table 4.36: Leading products in Alpharma's generics portfolio, 2004-05
- Table 4.37: Forecast sales of Alpharma's current generics portfolio, 2005-2011